1. Home
  2. EVF vs EDIT Comparison

EVF vs EDIT Comparison

Compare EVF & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Senior Income Trust

EVF

Eaton Vance Senior Income Trust

HOLD

Current Price

$5.29

Market Cap

95.9M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.14

Market Cap

213.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVF
EDIT
Founded
1998
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.9M
213.8M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
EVF
EDIT
Price
$5.29
$2.14
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.50
AVG Volume (30 Days)
93.3K
1.8M
Earning Date
01-01-0001
11-10-2025
Dividend Yield
10.68%
N/A
EPS Growth
N/A
N/A
EPS
0.94
N/A
Revenue
N/A
$46,383,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.20
$0.91
52 Week High
$6.84
$4.54

Technical Indicators

Market Signals
Indicator
EVF
EDIT
Relative Strength Index (RSI) 43.08 39.94
Support Level $5.24 $1.95
Resistance Level $5.32 $2.61
Average True Range (ATR) 0.03 0.13
MACD 0.00 -0.01
Stochastic Oscillator 50.00 28.03

Price Performance

Historical Comparison
EVF
EDIT

About EVF Eaton Vance Senior Income Trust

Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: